Q3 2026 . Management View. CEO Christopher Simon stated, "We delivered a strong quarter, and we are raising our full year rev ...

You’ve probably seen the videos on YouTube turning grapes into fireballs in the microwave. Well, there’s a pretty cool ...

Recent commentary around ADMA Biologics (ADMA) has centered on positive sentiment ahead of upcoming earnings, with expectations for earnings growth and continued progress across its plasma derived ...

ShaniOS maintains two separate environments. If an update - or anything - goes wrong with one environment, simply reboot and switch to the other.

Guillain-Barré Syndrome Presenting as Pseudo-Cerebellar Syndrome: A Case Report from a Resource-Limited Setting in Sub-Saharan Africa Guillain-Barré Syndrome (GBS) is the most frequent cause of acute ...

Haemonetics Corporation (NYSE: HAE) announced that financial results for its third quarter fiscal year 2026, which ended December 27, 2025, are available on the Company's Investor Relations website at ...

During the third day of a civil trial between Dr. Michael Joyner and Mayo Clinic, the president of Mayo Clinic Platform faced ...

If you've read my work enough, you know that I like my desktops to be elegant. This is one of the reasons why I was so excited for Apple to release Liquid Glass. It's one of the reasons why I believe ...

Haemonetics Corporation (NYSE:HAE) reported fiscal third-quarter 2026 results on Thursday that exceeded analyst expectations, ...

Designed to reinforce lucerastat as the first oral therapy suitable for all patients with Fabry disease, irrespective of their mutation type. The program is expected to support a potential regulatory ...

BOSTON - On Thursday, Haemonetics Corporation (NYSE:HAE) reported third quarter fiscal 2026 results that exceeded analyst expectations, with adjusted earnings per share of $1.31 surpassing the ...

IG market analyst Tony Sycamore told NewsWire it was a broad market sell-off across all assets in a broad “contagious” impact ...